Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.

Kankia IH, Khalil HS, Langdon SP, Moult PR, Bown JL, Deeni YY.

Oxid Med Cell Longev. 2017;2017:1864578. doi: 10.1155/2017/1864578. Epub 2017 Dec 19.

2.

Uncovering behavioural diversity amongst high-strength Pseudomonas spp. surfactants at the limit of liquid surface tension reduction.

Kabir K, Deeni YY, Hapca SM, Moore L, Spiers AJ.

FEMS Microbiol Lett. 2018 Feb 1;365(4). doi: 10.1093/femsle/fny008.

PMID:
29346641
3.

Biofilm formation and cellulose expression by Bordetella avium 197N, the causative agent of bordetellosis in birds and an opportunistic respiratory pathogen in humans.

McLaughlin K, Folorunso AO, Deeni YY, Foster D, Gorbatiuk O, Hapca SM, Immoor C, Koza A, Mohammed IU, Moshynets O, Rogalsky S, Zawadzki K, Spiers AJ.

Res Microbiol. 2017 Jun;168(5):419-430. doi: 10.1016/j.resmic.2017.01.002. Epub 2017 Jan 26.

PMID:
28131895
4.

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.

Khalil HS, Langdon SP, Goltsov A, Soininen T, Harrison DJ, Bown J, Deeni YY.

Oncotarget. 2016 Nov 15;7(46):75874-75901. doi: 10.18632/oncotarget.12425.

5.

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.

Khalil HS, Langdon SP, Kankia IH, Bown J, Deeni YY.

Oxid Med Cell Longev. 2016;2016:4148791. doi: 10.1155/2016/4148791. Epub 2015 Dec 7.

6.

The evolution of biofilm-forming Wrinkly Spreaders in static microcosms and drip-fed columns selects for subtle differences in wrinkleality and fitness.

Udall YC, Deeni Y, Hapca SM, Raikes D, Spiers AJ.

FEMS Microbiol Ecol. 2015 Jun;91(6). pii: fiv057. doi: 10.1093/femsec/fiv057. Epub 2015 May 21.

PMID:
26002784
7.

Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells.

Khalil HS, Goltsov A, Langdon SP, Harrison DJ, Bown J, Deeni Y.

J Biotechnol. 2015 May 20;202:12-30. doi: 10.1016/j.jbiotec.2014.09.027. Epub 2014 Nov 5.

PMID:
25449014
8.

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.

Goltsov A, Deeni Y, Khalil HS, Soininen T, Kyriakidis S, Hu H, Langdon SP, Harrison DJ, Bown J.

Cells. 2014 Jun 10;3(2):563-91. doi: 10.3390/cells3020563.

9.

Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity.

Deeni YY, Ibbotson SH, Woods JA, Wolf CR, Smith G.

PLoS One. 2013 Sep 23;8(9):e75494. doi: 10.1371/journal.pone.0075494. eCollection 2013.

10.

Engineering simulations for cancer systems biology.

Bown J, Andrews PS, Deeni Y, Goltsov A, Idowu M, Polack FA, Sampson AT, Shovman M, Stepney S.

Curr Drug Targets. 2012 Nov;13(12):1560-74. Review.

PMID:
22974398
11.

Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases.

Smith G, Wolf CR, Deeni YY, Dawe RS, Evans AT, Comrie MM, Ferguson J, Ibbotson SH.

Lancet. 2003 Apr 19;361(9366):1336-43.

PMID:
12711469

Supplemental Content

Loading ...
Support Center